Efficacy and safety of extemporaneously prepared miconazole eye drops in Candida albicans-induced keratomycosis

2017 ◽  
Vol 38 (5) ◽  
pp. 2089-2100 ◽  
Author(s):  
Linda Gyanfosu ◽  
George Asumeng Koffuor ◽  
Samuel Kyei ◽  
Ben Ababio-Danso ◽  
Kwabena Peprah-Donkor ◽  
...  
Keyword(s):  
Candida Albicans ◽  
Eye Drops ◽  
Efficacy And Safety

scholarly journals Efficacy and Safety of Topical Timolol Eye Drops in the Treatment of Myopic Regression after Laser In Situ Keratomileusis: A Systematic Review and Meta-Analysis

2015 ◽  
Vol 2015 ◽  
pp. 1-8 ◽  
Author(s):  
Xiaochen Wang ◽  
Guiqiu Zhao ◽  
Jing Lin ◽  
Nan Jiang ◽  
Qian Wang ◽  
...  
Keyword(s):  
Meta Analysis ◽  
Treated Group ◽  
Laser In Situ Keratomileusis ◽  
Control Group ◽  
Eye Drops ◽  
Efficacy And Safety ◽  
China National Knowledge Infrastructure ◽  
Knowledge Infrastructure ◽  
Significant Difference

Aims. The aim of this study was to assess the efficacy and safety of timolol in the treatment of myopic regression after laser in situ keratomileusis (LASIK).Methods. We searched MEDLINE, CENTRAL, EMBASE, China National Knowledge Infrastructure (CNKI), and Chinese Biological Medicine (CBM) from the inception to July 2015 for relevant randomized controlled trials that examined timolol therapy for myopic regression. The methodological quality of the studies included was assessed using the Revman 5.3 software.Results. We included six clinical trials involving 483 eyes in this review, including 246 eyes in treated group and 237 eyes in controlled group. We observed statistically significant improvements on the postoperative SE in the 3 months. However, the change of CCT was not statistically different between the control group and the experimental group. There were fewer cases of IOP, UDVA, and CDVA in treated group having significant difference from the controlled group.Conclusions. Topical timolol could be an effective treatment for reduction of myopic regression especially the spherical errors after myopic LASIK. Further RCTs with larger sample sizes for these trials are warranted to determine the efficacy and limitation for myopic regression after LASIK.

scholarly journals Candida albicans isolated from post-operative penetrating keratoplasty patient: Case report

2014 ◽  
Vol 5 (3) ◽  
pp. 116-119
Author(s):  
Abhishek Chandra ◽  
Munesh Kumar Gupta ◽  
Ragini Tilak
Keyword(s):  
Candida Albicans ◽  
Case Report ◽  
Amphotericin B ◽  
Penetrating Keratoplasty ◽  
Antifungal Susceptibility ◽  
Medical Science ◽  
Eye Drops ◽  
Gram Staining ◽  
Chlamydospore Formation ◽  
Culture Characteristics

We report a case report of Candida albicans suture infiltrate on 3rd post-op day in a 53 year female operated for penetrating keratoplasty. Candida albicans was identified by KOH mount, Gram Staining, germ tube, growth at 450C, chlamydospore formation and light green color on CHROMagar with sugar assimilation and culture characteristics. Despite being susceptible to Fluconazole by broth microdilution, patient did not respond to 0.3% fluconazole eye drops. On antifungal susceptibility testing by CLSI44A, it was susceptible to only Amphotericin B (100units). Patient was then started on 0.15% fortified amphotericin B eye drops resulting in complete resolution of infiltrates. Asian Journal of Medical Science, Volume-5(3) 2014: 116-119 http://dx.doi.org/10.3126/ajms.v5i3.8669 

scholarly journals A prospective study of efficacy and safety of olopatadine versus azelastine in allergic conjunctivitis at a tertiary care hospital

2017 ◽  
Vol 6 (8) ◽  
pp. 1948 ◽  
Author(s):  
Jayanthi C. R. ◽  
Nanthini R. ◽  
. Vijayalakshmi
Keyword(s):  
Mast Cell ◽  
Adverse Events ◽  
Allergic Conjunctivitis ◽  
Tertiary Care ◽  
Signs And Symptoms ◽  
Eye Drops ◽  
Care Hospital ◽  
Efficacy And Safety ◽  
H1 Receptor ◽  
Olopatadine Hydrochloride

Background: Allergic conjunctivitis, an ocular surface inflammatory disease with significant social and economic impact affects approximately 25% of the general population. H1 receptor blockers, mast cell stabilizers and drugs that block cytokine and prostaglandin formation form the treatment armamentarium. Olopatadine hydrochloride and Azelastine hydrochloride are dual-acting selective H1 receptor antagonist with mast-cell stabilizing property. This study was undertaken to assess the efficacy and safety of olopatadine hydrochloride 0.1% and Azelastine hydrochloride 0.05% in allergic conjunctivitis amongst Indians.Methods: After obtaining Institutional Ethics Committee approval and written informed consent, 120 patients diagnosed with allergic conjunctivitis fulfilling the inclusion/exclusion criteria were enrolled in the study. Study was done from April 2014 to June 2015 at Minto eye hospital. Study subjects were treated with olopatadine hydrochloride 0.1% and Azelastine hydrochloride 0.05% eye drops BD for 15 days. Ocular symptoms, instead of and signs and adverse events, if any were recorded on the day 8 and day 15 follow up visits.Results: At the end of the study period, the reduction in the ocular itching score from baseline was higher in the olopatadine group compared to the azelastine group (p<0.002). Similarly, the scores of ocular congestion (p<0.008), foreign body sensation (p<0.009), tearing (p<0.001), erythema (p<0.002) and chemosis (p<0.015) also showed larger reduction in the olopatadine treated patients. The common adverse events encountered in both the groups were stinging after instillation, burning, bitter taste and headache.Conclusions: In allergic conjunctivitis, both olopatadine and azelastine were found to be effective in relieving ocular signs and symptoms, but olopatadine was found to be superior in terms of efficacy, safety and tolerability with minimal side effects.

Prospective study comparing Xalatan® eye drops and two similar generics as to the efficacy and safety profile

2018 ◽  
Vol 28 (4) ◽  
pp. 378-384 ◽  
Author(s):  
Andreas Diagourtas ◽  
Kostantinos Kagelaris ◽  
Kostantinos Oikonomakis ◽  
Andreas Droulias ◽  
Nikolaos Kokolakis ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Safety Profile ◽  
Ocular Surface ◽  
Disease Index ◽  
Ocular Surface Disease ◽  
Eye Drops ◽  
Efficacy And Safety ◽  
Ocular Surface Disease Index ◽  
Significant Difference ◽  
The Mean

Purpose: To evaluate the efficacy and safety between two generic prostaglandins Lataz–Xalaprost (Greece) and the corresponding original drops (Xalatan®). Material and methods: In this prospective randomized study, 60 patients diagnosed with open-angle glaucoma or ocular hypertension were enrolled, who had never received antiglaucoma treatment. Subjects were divided randomly into three groups (Xalatan, Lataz, and Xalaprost groups) and they were studied over 16 weeks. At each visit, the mean applanation tonometry values and tear break-up time were measured. The Ocular Surface Disease Index questionnaire was used to evaluate patient’s symptoms. Results: There was a statistically significant difference (p < 0.001) in the mean values of the intraocular pressure between the baseline and the last visit (Xalatan group: from 23.11 ± 1.61 mmHg to 15.81 ± 1.22 mmHg, Lataz group: from 23.26 ± 1.33 mmHg to 15.80 ± 1.47 mmHg, and Xalaprost group: from 23.08 ± 1.45 mmHg to 16.08 ± 1.38 mmHg). Both generic eye drops showed mean percentage intraocular pressure reduction comparable to the standards of prostaglandin analogues (Xalatan: 31.57%, Lataz: 32.06%, and Xalaprost: 30.34%). Xalatan reduced the tear break-up time less, followed by Lataz and then by Xalaprost (Xalatan: from 8.5 to 8 s, Lataz: from 8.2 to 7.4 s, and Xalaprost: from 8.7 to 7.7 s). Xalatan presented the best safety profile, followed by Lataz and least was Xalaprost, according to Ocular Surface Disease Index questionnaire’s results. Conclusion: No significant difference was recorded in the effectiveness of each generic prostaglandin compared to the original. Furthermore, no patient had to change medication. The differences that arose in the safety profile of the three eye drops suggest a prompt closer initial monitoring of patients who are administered generic eye drops.

Sign in / Sign up

Export Citation Format

Share Document